Role and mechanism of action of the Mongolian medicine <i>Scabiosa atropurea</i> in inhibiting the proliferation of hepatic stellate cells

Yuxin YAN; Xiaoyang GAO; Chunyan ZHANG; Rong JIN; Hongwei YUAN; Yuehong MA

doi:10.3969/j.issn.1001-5256.2023.06.015

Volume 39 Issue 6

Jun. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(6): 1351-1357

PDF( 2342 KB)

Role and mechanism of action of the Mongolian medicine Scabiosa atropurea in inhibiting the proliferation of hepatic stellate cells

DOI: 10.3969/j.issn.1001-5256.2023.06.015

School of Basic Medical Sciences, Inner Mongolia Medical University, Hohhot 010000, China

Research funding:

National Natural Science Foundation of China (81960759);

National Natural Science Foundation of China (81560706);

Natural Science Foundation of Inner Mongolia Autonomous Region (2019MS08010);

Natural Science Foundation of Inner Mongolia Autonomous Region (2014MS0841);

Grassland Talent Cultivation Program of Inner Mongolia Autonomous Region (Human Resources and Social Security Office of Inner Mongolia[2016]348);

Zhiyuan Talent Project of Inner Mongolia Medical University (2020-11);

Inner Mongolia Talent Development Fund (2022-22056);

Science and Technology Innovation Team for Research on the Anti-Hepatic Fibrosis Effects of Mongolian Medicine at Inner Mongolia Medical University (2022-01);

Key Project of Inner Mongolia Medical University (YKD2022ZD019)

More Information

Corresponding author: MA Yuehong, myh19982002@sina.com (ORCID: 0000-0003-0699-378X)
Received Date: 2022-09-10
Accepted Date: 2023-02-01
Published Date: 2023-06-20

Abstract

Abstract

Objective To investigate the role and mechanism of action of Scabiosa atropurea in inhibiting the proliferation of hepatic stellate cells using cell experiment. Methods A total of 20 Wistar rats were randomly divided into control group and administration group, with 10 rats in each group. The rats in the control group were given normal saline by gavage, and those in the administration group were given Scabiosa atropurea by gavage to prepare drug-containing serum. HSC-T6 cells were incubated with the serum from the control group (10%) or the low-, middle-, and high-dose serum containing Scabiosa atropurea (10%, 15%, and 20%, respectively). MTT assay was used to observe the effect of different drug concentrations on cells in different periods of time; flow cytometry was used to measure cell apoptosis; qRT-PCR and Western blot were used to measure the mRNA and protein expression levels of fibrosis markers (α-SMA, collagen Ⅰ) and PI3K/Akt signaling pathway-related factors in hepatic stellate cells (HSCs). A one-way analysis of variance was used for comparison between multiple groups, and the least significant difference t- test was used for further comparison between two groups. Results Compared with the control group, the low-, middle-, and high-dose serum containing Scabiosa atropurea groups had a significant reduction in the OD value of cells (all P < 0.05) and a significant increase in the overall apoptosis rate of cells (all P < 0.05). The results of qRT-PCR showed that compared with the control group, the low-, middle-, and high-dose serum containing Scabiosa atropurea groups had significant reductions in the mRNA expression levels of α-SMA, collagen Ⅰ, PI3K, and Akt and a significant increase in the mRNA expression level of PTEN (all P < 0.05); Western blot showed that compared with the control group, the low-, middle-, and high-dose serum containing Scabiosa atropurea groups had significant reductions in the protein expression levels of α-SMA, collagen Ⅰ, PI3K, Akt, and p-Akt and a significant increase in the protein expression level of PTEN (all P < 0.05). Conclusion The Mongolian medicine Scabiosa atropurea can inhibit the proliferation of HSC-T6 cells and promote their apoptosis, possibly by regulating fibrosis markers and the PI3K/Akt signaling pathway to exert an anti-liver fibrosis effect.
- Hepatic Fibrosis,
- Hepatic Stellate Cells,
- Scabiosa Atropurea,
- Signal Transduction

FullText(HTML)

References(27)

References

[1]	ZHANG CY, YUAN WG, HE P, et al. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets[J]. World J Gastroenterol, 2016, 22(48): 10512-10522. DOI: 10.3748/wjg.v22.i48.10512.
[2]	TRAUTWEIN C, FRIEDMAN SL, SCHUPPAN D, et al. Hepatic fibrosis: Concept to treatment[J]. J Hepatol, 2015, 62(1 Suppl): S15-S24. DOI: 10.1016/j.jhep.2015.02.039.
[3]	HIGASHI T, FRIEDMAN SL, HOSHIDA Y. Hepatic stellate cells as key target in liver fibrosis[J]. Adv Drug Deliv Rev, 2017, 121: 27-42. DOI: 10.1016/j.addr.2017.05.007.
[4]	ZHANG M, SERNA-SALAS S, DAMBA T, et al. Hepatic stellate cell senescence in liver fibrosis: Characteristics, mechanisms and perspectives[J]. Mech Ageing Dev, 2021, 199: 111572. DOI: 10.1016/j.mad.2021.111572.
[5]	EZHILARASAN D, SOKAL E, NAJIMI M. Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(3): 192-197. DOI: 10.1016/j.hbpd.2018.04.003.
[6]	AYD₁N MM, AKÇAL₁ KC. Liver fibrosis[J]. Turk J Gastroenterol, 2018, 29(1): 14-21. DOI: 10.5152/tjg.2018.17330.
[7]	SCHUPPAN D, ASHFAQ-KHAN M, YANG AT, et al. Liver fibrosis: Direct antifibrotic agents and targeted therapies[J]. Matrix Biol, 2018, 68-69: 435-451. DOI: 10.1016/j.matbio.2018.04.006.
[8]	YANG HX, BAI YF, CHANG L, et al. Research progress on the resources and utilization of the Mongolian medicinal plant Cyperus genus[J]. Northwest Pharm J, 2020, 35(5): 779-784. DOI: 10.3969/j.issn.1004-2407.2020.05.031. 杨宏昕, 白音夫, 常亮, 等. 蒙药材蓝盆花属植物资源及利用的研究进展[J]. 西北药学杂志, 2020, 35(5): 779-784. DOI: 10.3969/j.issn.1004-2407.2020.05.031.
[9]	LU C, LI Y, CUI Y, et al. Isolation and functional analysis of genes involved in polyacylated anthocyanin biosynthesis in Blue Senecio cruentus[J]. Front Plant Sci, 2021, 12: 640746. DOI: 10.3389/fpls.2021.640746.
[10]	JAMES ANTONY JJ, ZAKARIA S, ZAKARIA R, et al. Biochemical analyses of Dendrobium Sabin Blue PLBs during cryopreservation by vitrification[J]. Physiol Mol Biol Plants, 2019, 25(6): 1457-1467. DOI: 10.1007/s12298-019-00703-2.
[11]	ZHANG CY, YAN YX, GAO XY, et al. Mechanism of anti- hepatic fibrosis action of the monk's medicine seven flavors liver clearing powder: based on UHPLC-TOF-MS and network pharmacology methods[J]. J South Med Univ, 2021, 41(8): 1131-1141. DOI: 10.12122/j.issn.1673-4254.2021.08.02. 张春艳, 颜羽昕, 高晓阳, 等. 蒙药七味清肝散抗肝纤维化的作用机制: 基于UHPLC-TOF-MS和网络药理学方法[J]. 南方医科大学学报, 2021, 41(8): 1131-1141. DOI: 10.12122/j.issn.1673-4254.2021.08.02.
[12]	LIANG J, MENG GSLM, YAN YX, et al. Study on the anti-hepatic fibrosis effect and mechanism of qiwei qinggan powder based on proteomics[J]. China Pharm, 2020, 31(11): 1294-1302. DOI: 10.6039/j.issn.1001-0408.2020.11.03. 梁洁, 孟根斯立木, 颜羽昕, 等. 基于蛋白质组学研究七味清肝散的抗肝纤维化作用及机制研究[J]. 中国药房, 2020, 31(11): 1294-1302. DOI: 10.6039/j.issn.1001-0408.2020.11.03.
[13]	ZHANG CY, JIN R, YAN YX, et al. Exploring the mechanism of action of Bluebonnets against liver fibrosis based on pharmacodynamic and network pharmacological approaches[J]. China J Chin Mater Med, 2022, 47(13): 3609-3618. DOI: 10.19540/j.cnki.cjcmm.20220207.702. 张春艳, 金蓉, 颜羽昕, 等. 基于药效学和网络药理方法探讨蓝盆花抗肝纤维化的作用机制[J]. 中国中药杂志, 2022, 47(13): 3609-3618. DOI: 10.19540/j.cnki.cjcmm.20220207.702.
[14]	LUBECKA K, FLOWER K, BEETCH M, et al. Loci-specific differences in blood DNA methylation in HBV-negative populations at risk for hepatocellular carcinoma development[J]. Epigenetics, 2018, 13(6): 605-626. DOI: 10.1080/15592294.2018.1481706.
[15]	TAO Y, WANG N, QIU T, et al. The role of autophagy and NLRP3 inflammasome in liver fibrosis[J]. Biomed Res Int, 2020, 2020: 7269150. DOI: 10.1155/2020/7269150.
[16]	ZHANG M, ZANG S. T cells in fibrosis and fibrotic diseases[J]. Front Immunol, 2020, 11: 1142. DOI: 10.3389/fimmu.2020.01142.
[17]	KOSTALLARI E, HIRSOVA P, PRASNICKA A, et al. Hepatic stellate cell-derived platelet-derived growth factor receptor-alpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2[J]. Hepatology, 2018, 68(1): 333-348. DOI: 10.1002/hep.29803.
[18]	MATSUDA M, SEKI E. Hepatic stellate cell-macrophage crosstalk in liver fibrosis and carcinogenesis[J]. Semin Liver Dis, 2020, 40(3): 307-320. DOI: 10.1055/s-0040-1708876.
[19]	KHOMICH O, IVANOV AV, BARTOSCH B. Metabolic hallmarks of hepatic stellate cells in liver fibrosis[J]. Cells, 2019, 9(1): 24. DOI: 10.3390/cells9010024.
[20]	SHI Z, ZHANG K, CHEN T, et al. Transcriptional factor ATF3 promotes liver fibrosis via activating hepatic stellate cells[J]. Cell Death Dis, 2020, 11(12): 1066. DOI: 10.1038/s41419-020-03271-6.
[21]	KAMM DR, MCCOMMIS KS. Hepatic stellate cells in physiology and pathology[J]. J Physiol, 2022, 600(8): 1825-1837. DOI: 10.1113/JP281061.
[22]	WANG R, SONG F, LI S, et al. Salvianolic acid A attenuates CCl₄-induced liver fibrosis by regulating the PI3K/AKT/mTOR, Bcl-2/Bax and caspase-3/cleaved caspase-3 signaling pathways[J]. Drug Des Devel Ther, 2019, 13: 1889-1900. DOI: 10.2147/DDDT.S194787.
[23]	WU H, CHEN G, WANG J, et al. TIM-4 interference in Kupffer cells against CCL4-induced liver fibrosis by mediating Akt1/Mitophagy signalling pathway[J]. Cell Prolif, 2020, 53(1): e12731. DOI: 10.1111/cpr.12731.
[24]	XIE Y, SHI X, SHENG K, et al. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review)[J]. Mol Med Rep, 2019, 19(2): 783-791. DOI: 10.3892/mmr.2018.9713.
[25]	PAPA A, PANDOLFI PP. The PTEN-PI3K axis in cancer[J]. Biomolecules, 2019, 9(4): 153. DOI: 10.3390/biom9040153.
[26]	XIU AY, DING Q, LI Z, et al. Doxazosin attenuates liver fibrosis by inhibiting autophagy in hepatic stellate cells via activation of the PI3K/Akt/mTOR signaling pathway[J]. Drug Des Devel Ther, 2021, 15: 3643-3659. DOI: 10.2147/DDDT.S317701.
[27]	LIU X, LIU W, DING C, et al. Taxifolin, extracted from waste larix olgensis roots, attenuates CCl4-induced liver fibrosis by regulating the PI3K/AKT/mTOR and TGF-β1/Smads signaling pathways[J]. Drug Des Devel Ther, 2021, 15: 871-887. DOI: 10.2147/DDDT.S281369.

Relative Articles

[1]	Kuan LI, Huibin NING, Huiming JIN, Zhen PENG, Jia SHANG. Effect of pegylated interferon α-2b on serum HBsAg clearance rate in treatment of patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(8): 1819-1824. doi: 10.3969/j.issn.1001-5256.2023.08.009
[2]	Peiyao FAN, Fuchuan WANG, Yinjie GAO, Zhiqiang XU, Yi DONG, Jianguo YAN, Lili CAO, Danni FENG, Yanwei ZHONG, Min ZHANG. Value of serum PreS1 in early prediction of HBsAg clearance after IFN-α treatment in children with HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(8): 1825-1831. doi: 10.3969/j.issn.1001-5256.2023.08.010
[3]	Wei ZHU, Xiaoyong ZHANG, Daqian ZHANG, Jinlin HOU. Strategies and advances in targeting adaptive immunity to cure chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(5): 1016-1021. doi: 10.3969/j.issn.1001-5256.2021.05.005
[4]	Hong ZHANG, Xiaoxue ZHU, Jiajia MAI, Hong CHEN, Jing ZHOU, Yue HU, Jia XU, Yanhua DING. Clinical studies of new antiviral drugs for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(5): 1006-1010. doi: 10.3969/j.issn.1001-5256.2021.05.003
[5]	Kaimin SONG, Jun LIU. Advances in the application of transient elastography in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(2): 419-424. doi: 10.3969/j.issn.1001-5256.2021.02.036
[6]	Xuefu CHEN, Dongjing ZHANG, Xiaodan LUO, Ren CHEN. Current status of the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(5): 1011-1015. doi: 10.3969/j.issn.1001-5256.2021.05.004
[7]	Weili NIU, Yongsu WANG, Qingshan WU, Lin ZHANG, Zhongqin ZHANG, Xiaojun YANG, Xianbin ZHU, Wenqin XIAO, Mingping JI. A clinical study of clinical cure after the addition of interferon therapy in chronic hepatitis B patients with low-level HBsAg previously treated with nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2021, 37(8): 1793-1797. doi: 10.3969/j.issn.1001-5256.2021.08.010
[8]	Tian ZHANG, Sijing JIA, Dongxue SUN, Fengxi LONG, Dongxin TANG, Zhu YANG. Mechanism of "Szechwan Chinaberry Fruit-Rhizoma Corydalis" drug combination in treatment of liver cancer based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(9): 2136-2143. doi: 10.3969/j.issn.1001-5256.2021.09.026
[9]	Tingting ZHANG, Jue ZHAO, Yan YANG, Yaojie KANG, Xuan WANG. Type 1 diabetes mellitus due to pegylated interferon treatment of chronic hepatitis B: A case report[J]. Journal of Clinical Hepatology, 2021, 37(8): 1905-1906. doi: 10.3969/j.issn.1001-5256.2021.08.031
[10]	Qiuluo CHENG, Liu LIU, Changchuan BAI, Qingwei CONG, Ying ZHU. Mechanism of action of five classic prescriptions in treatment of hepatocellular carcinoma based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(8): 1848-1855. doi: 10.3969/j.issn.1001-5256.2021.08.020
[11]	Shaohang LAN, Qiuyuan TANG, Nana LI, Ran TAO, Nansheng LIAO, Yinjie MENG, Cao HE, Dewen MAO. Mechanism of action of Xiaochaihu decoction in the treatment of hepatitis B based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(10): 2308-2315. doi: 10.3969/j.issn.1001-5256.2021.10.010
[12]	Le TIAN, Yinghang WANG, Zhi PAN. Mechanism of Xiaozheng Huoluo prescription in preventing liver fibrosis in rats via the ERK5 pathway: An analysis based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(3): 582-589. doi: 10.3969/j.issn.1001-5256.2021.03.016
[13]	Jingshu QI, Dabing PING, Xin SUN, Jingbo XUE, Yanyan TAO, Yuan PENG, Chenghai LIU. Mechanism of action of Fuzheng Huayu prescription in treatment of liver cancer based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(10): 2338-2342. doi: 10.3969/j.issn.1001-5256.2021.10.016
[14]	Li Jing, Mo JiaHao, Xu HongBin, Zhu JunXia, Shi PeiYu, Xing WanLi, Zhong Chong, Lin LiZhu. Mechanism of action of Sini powder in treatment of liver cancer based on network pharmacology and molecular docking[J]. Journal of Clinical Hepatology, 2020, 36(9): 1998-2004. doi: 10.3969/j.issn.1001-5256.2020.09.018
[15]	Mu LiYa, Tang XiuFen, Li ShuQin, Yu Dan, Sun YuanYuan, Zhao JinHua. Clinical effects of bone marrow stem cell transplantation through different approaches in mice with acute liver injury[J]. Journal of Clinical Hepatology, 2019, 35(1): 153-156. doi: 10.3969/j.issn.1001-5256.2019.01.029
[16]	Lu Xin, Liu Ying, Jia Lei, Kong LingYu, Liu DianQing. Role of D-bifunctional protein in promoting the growth of hepatocellular carcinoma in rats and nude mice[J]. Journal of Clinical Hepatology, 2019, 35(7): 1532-1535. doi: 10.3969/j.issn.1001-5256.2019.07.022
[17]	Huang HaiYan, Xin YongNing, Jiang Man, Jin WenWen, Jiang XiangJun, Xuan ShiYing. Research advances in animal models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(9): 948-953. doi: 10.3969/j.issn.1001-5256.2014.09.028

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (487) PDF downloads(31)

Role and mechanism of action of the Mongolian medicine Scabiosa atropurea in inhibiting the proliferation of hepatic stellate cells

DOI: 10.3969/j.issn.1001-5256.2023.06.015

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role and mechanism of action of the Mongolian medicine Scabiosa atropurea in inhibiting the proliferation of hepatic stellate cells

DOI: 10.3969/j.issn.1001-5256.2023.06.015

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content